AN2 Therapeutics reports data fro previously terminated EBO-301 Study

AN2 Therapeutics (ANTX) “announced topline results from the Phase 3 portion of the EBO-301 study evaluating epetraborole on top of an optimized background regimen in treatment-refractory MAC lung disease. The truncated Phase 3 portion of the study did not meet its primary endpoint on improvement of Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome instrument (change from baseline to month 6). The study population included patients with severe, advanced MAC lung disease with a long duration of disease, high rates of cavitary/fibrocavitary disease, and multidrug resistance to standard of care antibiotics at baseline.” “While we’re disappointed in these results, we believe there is potential for epetraborole in other NTM populations, such as M. abscessus lung disease, and are pursuing nondilutive means to advance potential clinical development. Going forward, we have made significant progress on our boron chemistry pipeline with several high impact clinical programs in infectious diseases and an emerging oncology portfolio that give us multiple pathways to success,” said Eric Easom, Co-founder, Chairman, President and CEO.” Our clinical programs in Chagas and melioidosis feature first-in-class molecules with the potential to significantly reduce the mortality and impact of these devastating diseases. We also have leveraged our boron chemistry capabilities to identify multiple oncology candidates including potentially best-in-class inhibitors for ENPP1 and PI3Kalpha with our lead compound(s) expected to enter development later this year. These opportunities, driven by cutting-edge boron chemistry, feature strong intellectual property rights and have the potential to significantly enhance our Company’s value within our existing cash runway.”